Joel A Sincavage
Supervisory Patent Examiner (ID: 11124, Phone: (571)272-2610 , Office: P/2910 )
Most Active Art Unit | 2911 |
Art Unit(s) | 2911, 2900, 2901, 2910 |
Total Applications | 4082 |
Issued Applications | 4006 |
Pending Applications | 1 |
Abandoned Applications | 75 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 13508347
[patent_doc_number] => 20180305716
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-25
[patent_title] => METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS
[patent_app_type] => utility
[patent_app_number] => 16/008991
[patent_app_country] => US
[patent_app_date] => 2018-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21627
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 89
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16008991
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/008991 | Methods and compositions for the activation of gamma-delta T-cells | Jun 13, 2018 | Issued |
Array
(
[id] => 16290340
[patent_doc_number] => 10767177
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-08
[patent_title] => Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/002034
[patent_app_country] => US
[patent_app_date] => 2018-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56046
[patent_no_of_claims] => 59
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16002034
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/002034 | Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof | Jun 6, 2018 | Issued |
Array
(
[id] => 15866913
[patent_doc_number] => 20200140860
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => IncRNAs GADLOR 1 AND 2 FOR USE IN TREATING AND PREVENTING CARDIAC REMODELLING
[patent_app_type] => utility
[patent_app_number] => 16/616398
[patent_app_country] => US
[patent_app_date] => 2018-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24405
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616398
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/616398 | IncRNAs GADLOR 1 and 2 for use in treating and preventing cardiac remodelling | May 29, 2018 | Issued |
Array
(
[id] => 16091271
[patent_doc_number] => 20200199622
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => VIRAL VECTOR PRODUCTION
[patent_app_type] => utility
[patent_app_number] => 16/612497
[patent_app_country] => US
[patent_app_date] => 2018-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9568
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612497
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/612497 | Viral vector production | May 10, 2018 | Issued |
Array
(
[id] => 15963715
[patent_doc_number] => 20200165609
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-28
[patent_title] => METHODS OF IDENTIFYING MIRNAS AND APPLICATIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/611293
[patent_app_country] => US
[patent_app_date] => 2018-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34220
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16611293
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/611293 | METHODS OF IDENTIFYING MIRNAS AND APPLICATIONS THEREOF | May 9, 2018 | Abandoned |
Array
(
[id] => 14159185
[patent_doc_number] => 20190106695
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-11
[patent_title] => OLIGONUCLEOTIDE COMPOSITIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/976333
[patent_app_country] => US
[patent_app_date] => 2018-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19733
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15976333
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/976333 | Oligonucleotide compositions and uses thereof | May 9, 2018 | Issued |
Array
(
[id] => 16855186
[patent_doc_number] => 20210155931
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-27
[patent_title] => TREATMENT OF RAPIDLY EVOLVING BIOLOGICAL ENTITIES
[patent_app_type] => utility
[patent_app_number] => 16/612161
[patent_app_country] => US
[patent_app_date] => 2018-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15550
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612161
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/612161 | TREATMENT OF RAPIDLY EVOLVING BIOLOGICAL ENTITIES | May 6, 2018 | Abandoned |
Array
(
[id] => 13827125
[patent_doc_number] => 20190017047
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-17
[patent_title] => METHODS FOR MODULATING ATAXIN 2 EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 15/973088
[patent_app_country] => US
[patent_app_date] => 2018-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19991
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15973088
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/973088 | Methods for modulating Ataxin 2 expression | May 6, 2018 | Issued |
Array
(
[id] => 16013551
[patent_doc_number] => 20200181618
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => FLUOROGEN-BINDING RNA APTAMERS
[patent_app_type] => utility
[patent_app_number] => 16/608127
[patent_app_country] => US
[patent_app_date] => 2018-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25747
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 427
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16608127
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/608127 | Fluorogen-binding RNA aptamers | Apr 22, 2018 | Issued |
Array
(
[id] => 13987161
[patent_doc_number] => 20190062738
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-28
[patent_title] => Method and System for the Diagnosis, Prevention or Treatment of Alzheimer s and Related Disease by Measuring, Inhibiting or Arresting Amyloid Plaque Development
[patent_app_type] => utility
[patent_app_number] => 15/954570
[patent_app_country] => US
[patent_app_date] => 2018-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4834
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -72
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15954570
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/954570 | Method and System for the Diagnosis, Prevention or Treatment of Alzheimer s and Related Disease by Measuring, Inhibiting or Arresting Amyloid Plaque Development | Apr 15, 2018 | Abandoned |
Array
(
[id] => 16253810
[patent_doc_number] => 20200263184
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING MALATE-ASPARTATE SHUTTLE INHIBITOR AND ANTICANCER DRUG AS ACTIVE INGREDIENTS
[patent_app_type] => utility
[patent_app_number] => 16/604847
[patent_app_country] => US
[patent_app_date] => 2018-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8459
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604847
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/604847 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING MALATE-ASPARTATE SHUTTLE INHIBITOR AND ANTICANCER DRUG AS ACTIVE INGREDIENTS | Apr 12, 2018 | Abandoned |
Array
(
[id] => 17287071
[patent_doc_number] => 11203611
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-21
[patent_title] => Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
[patent_app_type] => utility
[patent_app_number] => 15/953290
[patent_app_country] => US
[patent_app_date] => 2018-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 105
[patent_figures_cnt] => 181
[patent_no_of_words] => 88385
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15953290
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/953290 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | Apr 12, 2018 | Issued |
Array
(
[id] => 16808294
[patent_doc_number] => 20210130847
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => METHOD FOR REDUCING THE EXPRESSION OF NKCC1 IN A SUBJECT
[patent_app_type] => utility
[patent_app_number] => 16/604648
[patent_app_country] => US
[patent_app_date] => 2018-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7725
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604648
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/604648 | Method for reducing the expression of NKCC1 in a subject | Apr 10, 2018 | Issued |
Array
(
[id] => 13493685
[patent_doc_number] => 20180298385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-18
[patent_title] => Methods for Treatment of Alport Syndrome
[patent_app_type] => utility
[patent_app_number] => 15/948450
[patent_app_country] => US
[patent_app_date] => 2018-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17084
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15948450
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/948450 | Methods for Treatment of Alport Syndrome | Apr 8, 2018 | Abandoned |
Array
(
[id] => 16720423
[patent_doc_number] => 20210087570
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-25
[patent_title] => FURTHER NOVEL OLIGONUCLEOTIDE-LIGAND CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 16/603211
[patent_app_country] => US
[patent_app_date] => 2018-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20323
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16603211
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/603211 | Further novel oligonucleotide-ligand conjugates | Apr 4, 2018 | Issued |
Array
(
[id] => 18329543
[patent_doc_number] => 11634772
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-25
[patent_title] => Antidote-mediated reversal of extracellular aptamer staining
[patent_app_type] => utility
[patent_app_number] => 16/496871
[patent_app_country] => US
[patent_app_date] => 2018-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 40
[patent_no_of_words] => 15165
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 129
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496871
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/496871 | Antidote-mediated reversal of extracellular aptamer staining | Mar 22, 2018 | Issued |
Array
(
[id] => 17178583
[patent_doc_number] => 11155818
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-10-26
[patent_title] => MicroRNA hsa-miR-665 in cardiac hypertrophy
[patent_app_type] => utility
[patent_app_number] => 16/493569
[patent_app_country] => US
[patent_app_date] => 2018-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 6211
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16493569
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/493569 | MicroRNA hsa-miR-665 in cardiac hypertrophy | Mar 12, 2018 | Issued |
Array
(
[id] => 13413901
[patent_doc_number] => 20180258493
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-13
[patent_title] => METHODS AND KITS FOR ASSESSING THE RISK OF DEVELOPING OR DIAGNOSING ENDOMETRIAL CANCER
[patent_app_type] => utility
[patent_app_number] => 15/917458
[patent_app_country] => US
[patent_app_date] => 2018-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6302
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15917458
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/917458 | Methods and kits for assessing the risk of developing or diagnosing endometrial cancer | Mar 8, 2018 | Issued |
Array
(
[id] => 13300791
[patent_doc_number] => 20180201932
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-07-19
[patent_title] => ALBUMIN PRODUCTION AND CELL PROLIFERATION
[patent_app_type] => utility
[patent_app_number] => 15/915275
[patent_app_country] => US
[patent_app_date] => 2018-03-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22171
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15915275
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/915275 | Albumin production and cell proliferation | Mar 7, 2018 | Issued |
Array
(
[id] => 13551847
[patent_doc_number] => 20180327471
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-15
[patent_title] => TRANSLATABLE MOLECULES AND SYNTHESIS THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/907123
[patent_app_country] => US
[patent_app_date] => 2018-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34022
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15907123
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/907123 | Translatable molecules and synthesis thereof | Feb 26, 2018 | Issued |